ClinicalTrials.gg
CompletedNCT04629690SOLARUpdated Jun 13, 2023

SOLAR- Frailty Screening and Multidisciplinary Assessment of Older Adults in the Emergency Department

An interventional study of SOLAR in Frailty, sponsored by University of Limerick. Completed at 1 site in Ireland. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2023-06-13.

Sponsored by University of Limerick · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
229
Allocation
Randomized
Ages
75 Years and older
Sex
All
01

Study summary

SOLAR is a randomised control trial exploring the role of Comprehensive Geriatric Assessment (CGA) in older adults who screen positive for frailty based on the Identification of Seniors at Risk (ISAR) tool the the Emergency Department and Acute Medical Assessment Unit of a University Teaching Hospital.

Read the detailed description

All patients who are over seventy-five will be screened for frailty using the widely used ISAR tool. Those with a score of 2 or above in the ISAR will be randomised. The treatment arm will undergo geriatric medicine team-directed CGA from admission to Emergency Department (ED) or Acute Medical Assessment Unit (AMAU) whereby the non-treatment arm will undergo usual patient care. A dedicated multidisciplinary team of a geriatric medicine trainee, physiotherapist, occupational therapist and medical social worker will carry out the assessment, as well as interventions that arise from that assessment. Primary outcomes will be time from triage to decision to admit or discharge. Secondary Outcomes will be subsequent Emergency Department reattendance, rehospitalisation, functional decline and mortality at 30 days and 180 days. This will be recorded by telephone consultation and electronic records.

02

Conditions studied

  • Frailty

Keywords

  • Comprehensive Geriatric Assessment
  • Emergency Department
  • Older Adults
  • Frailty
03

In context

Frailty

1,229 studies on the registry are indexed under Frailty; 433 are open to participants now.

This study's enrollment of 229 is above the median of 80 across 704 interventional studies indexed under Frailty.

Browse Frailty studies →

Lead sponsor

University of Limerick is the lead sponsor of 60 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
75 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Older adults aged 75 years or over
  • Medically stable as deemed by the treating physician
  • A score of 2 or above on the ISAR
  • Present with a medical complaint

Exclusion criteria

Exclusion Criteria:

  • Those under the age of 75 years
  • A score of less than 2 on the ISAR
  • Acute myocardial infarction, stroke or non-medical problems e.g. surgical or psychiatric issues
  • Patients who are medically unstable
  • If neither the patient nor carer can communicate in English sufficiently to complete consent or baseline assessment
  • Confirmed or highly suspicious of symptoms for COVID 19.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
229 participants (actual)

Study arms

  • No intervention
    Control Arm

    The control group will obtain usual medical care in the Emergency Department and Acute Medical Assessment Unit

  • Experimental
    SOLAR arm

    The SOLAR arm will obtain a comprehensive geriatric assessment which will be provided by a geriatric doctor, physiotherapist, occupational therapist, social worker, pharmacist and specialist nurse.

    Other: SOLAR

Interventions

  • OtherSOLAR

    The participants will obtain a multidisciplinary assessment regarding their medical conditions, medication review, cognitive assessment, functional assessment, gait and balance assessment by senior clinicians and a management plan will be implemented.

    Also known as: Comprehensive Geriatric Assessment

06

What researchers measure

Primary outcomes

  1. Patient Experience Times (PET)

    PET time recorded as time of arrival at the ED to discharge or admission

    Time frame: Exact time of admission or discharge from ED will be collected at 30 days from index visit

  2. Time to admission or discharge and if for admission, time that the bed is booked to go to medical wards.

    This is the time that the patient is either discharged or identified for admission and bed booked to go to the medical wards

    Time frame: Exact time of admission or discharge from ED will be collected at 30 days from index visit

Secondary outcomes

  1. Rate of ED Representation

    A record of the patient coming back to the ED within 30 days and/or 6 months

    Time frame: 30 days and 6 months

  2. Mortality

    A record of the patient having died within 30 days or 6 months

    Time frame: 30 days and 6 months

  3. Rate of Hospital Readmission

    A record of the patient requiring admission to the hospital within 30 days or 6 months

    Time frame: 30 days and 6 months

  4. Functional Decline

    As determined by the Barthel Index. Barthel Index is a score from 0-20. A score of 0 is completely dependent, 20 is fully independent.

    Time frame: 30 days and 6 months

  5. Patient Satisfaction-

    As determined by the Patient Satisfaction Survey III Short Form (PSQ18). This is scored from 18 to 90. 18 being the worst score and 90 being the best score.

    Time frame: 30 days

  6. Patient Quality of Life

    As determined by the Euro Quality of Life (Qol) EQ5D. Scored from 0 to 100. 0 is worst imaginable health state with 100 being the best imaginable health state

    Time frame: 30 days

  7. Number of visits to family doctor, therapists or public health nurse

    Determined by self reported visits to family doctor, allied health services or Public Health Nurse. There will be a telephone consultation at 30 days and 6 months where patients will be asked if they have visited a family doctor, therapist or public health nurse in the previous 30 days at the 30 day telephone call, or 6 months at the 6 month phone call.

    Time frame: 30 days and 6 months

07

Study locations

1 site
  • University Hospital Limerick
    Limerick, v, Ireland
08

References and documents

Publications

  • McCusker J, Bellavance F, Cardin S, Trepanier S, Verdon J, Ardman O. Detection of older people at increased risk of adverse health outcomes after an emergency visit: the ISAR screening tool. J Am Geriatr Soc. 1999 Oct;47(10):1229-37. doi: 10.1111/j.1532-5415.1999.tb05204.x. PubMed 10522957 ↗
  • Leahy A, Barry L, Corey G, Whiston A, Purtill H; SOLAR team; Shanahan E, Shchetkovsky D, Ryan D, O'Loughlin M, O'Connor M, Galvin R. Frailty screening with comprehensive geriatrician-led multidisciplinary assessment for older adults during emergency hospital attendance in Ireland (SOLAR): a randomised controlled trial. Lancet Healthy Longev. 2024 Nov;5(11):100642. doi: 10.1016/j.lanhl.2024.100642. Epub 2024 Nov 11. PubMed 39541993 ↗
  • Leahy A, McNamara R, Reddin C, Corey G, Carroll I; SOLAR team; O'Neill A, Flannery D, Devlin C, Barry L, MacCarthy B, Cummins N, Shanahan E, Shchetkovsky D, Ryan D, O'Connor M, Galvin R. The impact of frailty Screening of Older adults with muLtidisciplinary assessment of those At Risk during emergency hospital attendance on the quality, safety and cost-effectiveness of care (SOLAR): a randomised controlled trial. Trials. 2021 Aug 31;22(1):581. doi: 10.1186/s13063-021-05525-w. PubMed 34465368 ↗

Individual participant data

Plan to share: Yes — Individual data will be stored on a data repository after the study analysis.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: The study protocol will be prepared for publication in an open access journal. the study protocol will include the Statistical Analysis Plan and Informed Consent Form. It is likely to be published in Quarter 2 of 2021. The Clinical Study Report will be made publicly available in the form of a peer reviewed publication in late 2021.

Access criteria: Supporting information will be available on peer reviewed publications.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in May 2021, 6 months.

Of 477 non-industry interventional studies with no phase under Frailty, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 40. This study's 6 months is below that.

Counting every sponsor, half of 484 studies reached it within 21 months; a quarter within 9 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2020
First posted
Nov 16, 2020
StartActual
Nov 9, 2020
Primary completionActual
May 13, 2021
CompletionActual
Jan 15, 2023
Last update
Jun 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04629690
Lead sponsor
University of Limerick
Collaborators
University Hospital of Limerick
Responsible party
Sponsor
First posted
Nov 16, 2020
Start date
Nov 9, 2020
Primary completion
May 13, 2021
Completion
Jan 15, 2023
Last update
Jun 13, 2023

Study contacts

Rose Galvin, phD
principal investigator · University of Limerick

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion